Education
About Us
Working with TipRanks
Follow Us
Neximmune, Inc. (NEXI)
:NEXI
NEXI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.10 - $1.88
Previous CloseN/A
Volume4.35K
Average Volume (3M)148.00
Market Cap
$139.00
Enterprise Value-$2.42M
Total Cash (Recent Filing)$2.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-244.27
Shares Outstanding1,394,671
10 Day Avg. Volume0
30 Day Avg. Volume148
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-17.44K
Enterprise Value/Revenue-0.38
Enterprise Value/Gross Profit-1.60
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NexImmune News
PremiumCompany Announcements
NexImmune Dissolution Progresses with New Sole President
PremiumCompany Announcements
NexImmune Announces Leadership Shift in Financial Management
PremiumCompany Announcements
NexImmune Announces New Offerings in Recent Press Release
PremiumCompany Announcements
NexImmune Delays Liquidation Vote for Financing Review
PremiumCompany Announcements
NexImmune Equity Sales: Unregistered Securities and Private PlacementPremiumCompany Announcements
NexImmune Secures Funding Through Equity and Warrant Sales
PremiumCompany Announcements
NexImmune Ends Stock Sale Agreement, Raises $5.1 MillionOptions Prices
Currently, No data available
---
Ownership Overview
<0.01% Insiders
0.36% Mutual Funds
7.35% Other Institutional Investors
92.29% Public Companies and
Individual Investors
NEXI FAQ
What was Neximmune, Inc.’s price range in the past 12 months?
Neximmune, Inc. lowest stock price was $0.10 and its highest was $1.88 in the past 12 months.
What is Neximmune, Inc.’s market cap?
Neximmune, Inc.’s market cap is $139.00.
When is Neximmune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neximmune, Inc.’s earnings last quarter?
Neximmune, Inc. released its earnings results on May 13, 2024. The company reported -$2.461 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.461.
Is Neximmune, Inc. overvalued?
According to Wall Street analysts Neximmune, Inc.’s price is currently Overvalued.
Does Neximmune, Inc. pay dividends?
Neximmune, Inc. does not currently pay dividends.
What is Neximmune, Inc.’s EPS estimate?
Neximmune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neximmune, Inc. have?
Neximmune, Inc. has 1,394,671 shares outstanding.
What happened to Neximmune, Inc.’s price movement after its last earnings report?
Neximmune, Inc. reported an EPS of -$2.461 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.197%.
Which hedge fund is a major shareholder of Neximmune, Inc.?
Currently, no hedge funds are holding shares in NEXI
Company Description
Neximmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Quoin Pharmaceuticals
―
Evaxion Biotech
―
GRI Bio
―